Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS

UDC.coleccionInvestigación
UDC.departamentoFisioterapia, Medicina e Ciencias Biomédicas
UDC.endPage379
UDC.grupoInvInvestigación en Microbiología (INIBIC)
UDC.institutoCentroINIBIC - Instituto de Investigacións Biomédicas de A Coruña
UDC.issue2
UDC.journalTitleJournal of Antimicrobial Chemotherapy
UDC.startPage370
UDC.volume76
dc.contributor.authorHernández-García, Marta
dc.contributor.authorGarcía-Castillo, María
dc.contributor.authorGarcía-Fernández, Sergio
dc.contributor.authorMelo-Cristino, José
dc.contributor.authorPinto, Margarida Feijó
dc.contributor.authorGonçalves, Elsa
dc.contributor.authorAlves, Valquíria
dc.contributor.authorVieira, Ana Raquel
dc.contributor.authorRamalheira, Elmano
dc.contributor.authorSancho, Luísa
dc.contributor.authorDiogo, José
dc.contributor.authorFerreira, Rui
dc.contributor.authorSilva, Tania
dc.contributor.authorChaves, Catarina
dc.contributor.authorBou, Germán
dc.contributor.authorCercenado, Emilia
dc.contributor.authorDelgado-Valverde, Mercedes
dc.contributor.authorOliver, Antonio
dc.contributor.authorPitart, Cristina
dc.contributor.authorRodríguez-Lozano, Jesús
dc.contributor.authorTormo, Nuria
dc.contributor.authorRomano, Joao
dc.contributor.authorPássaro, Leonor
dc.contributor.authorPaixao, Laura
dc.contributor.authorLópez-Mendoza, Diego
dc.contributor.authorDíaz-Regañón, Jazmín
dc.contributor.authorCantón, Rafael
dc.date.accessioned2025-10-30T10:15:04Z
dc.date.available2025-10-30T10:15:04Z
dc.date.issued2020-10-25
dc.description.abstract[Abstract] Objectives: To analyse the epidemiology, the resistome and the virulome of ceftolozane/tazobactam-susceptible or -resistant Pseudomonas aeruginosa clinical isolates recovered from surveillance studies in Portugal (STEP, 2017-18) and Spain (SUPERIOR, 2016-17). Methods: P. aeruginosa isolates were recovered from intra-abdominal, urinary tract and lower respiratory tract infections in ICU patients admitted to 11 Portuguese and 8 Spanish hospitals. MICs were determined (ISO-standard broth microdilution, EUCAST 2020 breakpoints). A subset of 28 ceftolozane/tazobactam-resistant P. aeruginosa isolates were analysed and compared with 28 ceftolozane/tazobactam-susceptible P. aeruginosa strains by WGS. Results: Clonal complex (CC) 235 (27%) and CC175 (18%) were the most frequent, followed by CC244 (13%), CC348 (9%), CC253 (5%) and CC309 (5%). Inter-hospital clonal dissemination was observed, limited to a geographical region (CC235, CC244, CC348 and CC253 in Portugal and CC175 and CC309 in Spain). Carbapenemases were detected in 25 isolates (45%): GES-13 (13/25); VIM type (10/25) [VIM-2 (4/10), VIM-20 (3/10), VIM-1 (2/10) and VIM-36 (1/10)]; and KPC-3 (2/25). GES-13-CC235 (13/15) and VIM type-CC175 (5/10) associations were observed. Interestingly, KPC-3 and VIM-36 producers showed ceftolozane/tazobactam-susceptible phenotypes. However, ceftolozane/tazobactam resistance was significantly associated with GES-13 and VIM-type carbapenemase production. Six non-carbapenemase producers also displayed ceftolozane/tazobactam resistance, three of them showing known ceftolozane/tazobactam resistance-associated mutations in the PBP3 gene, ftsI (R504C and F533L). Overall, an extensive virulome was identified in all P. aeruginosa isolates, particularly in carbapenemase-producing strains. Conclusions: GES-13-CC235 and VIM type-CC175 were the most frequent MDR/XDR P. aeruginosa clones causing infections in Portuguese and Spanish ICU patients, respectively. Ceftolozane/tazobactam resistance was mainly due to carbapenemase production, although mutations in PBP-encoding genes may additionally be involved.
dc.description.sponsorshipThe study was funded by MSD Portugal (protocol VP6918) and MSD Spain (protocol MSD-CEF-2016-01). This study was also supported by Plan Nacional de I + D + i 2013–16 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases [RD16/0016/0001, RD16/0016/0004, RD16/0016/0006, RD16/0016/0007, RD16/0016/0010 and REIPI RD16/0016/0011], co-financed by the European Development Regional Fund ‘A way to achieve Europe’ (EDRF), Operative Program Intelligent Growth 2014–20. M.H.-G. is supported by a research contract from a European Project [IMI-JU-9–2013, Ref. iABC - 115721–2].
dc.identifier.citationHernández-García M, García-Castillo M, García-Fernández S, Melo-Cristino J, Pinto MF, Gonçalves E, Alves V, Vieira AR, Ramalheira E, Sancho L, Diogo J, Ferreira R, Silva T, Chaves C, Bou G, Cercenado E, Delgado-Valverde M, Oliver A, Pitart C, Rodríguez-Lozano J, Tormo N, Romano J, Pássaro L, Paixão L, López-Mendoza D, Díaz-Regañón J, Cantón R; STEP and SUPERIOR study groups. Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS. J Antimicrob Chemother. 2021 Jan 19;76(2):370-379.
dc.identifier.doi10.1093/jac/dkaa430
dc.identifier.issn0305-7453
dc.identifier.urihttps://hdl.handle.net/2183/46187
dc.language.isoeng
dc.publisherOxford University Press
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//RD16%2F0016%2F0001/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS/
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//RD16%2F0016%2F0004/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS/
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//RD16%2F0016%2F0006/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS/
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//RD16%2F0016%2F0007/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS/
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//RD16%2F0016%2F0010/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS/
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//RD16%2F0016%2F0011/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS/
dc.relation.urihttps://doi.org/10.1093/jac/dkaa430
dc.rightsThis is a pre-copyedited, author-produced version of an article accepted for publication in Journal of Antimicrobial Chemotherapy following peer review. The version of record is available online at Oxford Academic web page.
dc.rights.accessRightsopen access
dc.subjectPseudomonas infections
dc.subjectPseudomonas aeruginosa
dc.titleDistinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS
dc.typejournal article
dc.type.hasVersionAM
dspace.entity.typePublication
relation.isAuthorOfPublication909e08d1-6ed1-4b99-9e9e-c64eb72e7dea
relation.isAuthorOfPublication.latestForDiscovery909e08d1-6ed1-4b99-9e9e-c64eb72e7dea

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
HGarcia_Distinct_2021.pdf
Size:
1.08 MB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
HGarcia_Distinct_2021.zip
Size:
221.47 KB
Format:
Description:
Supplementary data